5-氨基乙酰丙酸引导胶质母细胞瘤切除后立即局部烷化剂化疗未提供额外获益
该回顾性队列研究纳入2009年7月至2014年12月间260例经5-氨基乙酰丙酸(5-ALA)引导切除、病理证实为WHO 2007 IV级胶质瘤的患者,采用倾向性评分匹配分析比较放置卡莫司汀 wafer 与否的生存差异,结果显示卡莫司汀 wafer 无显著生存获益(HR 0.97 [0.68-1.26],p=0.836),伤口感染发生率有升高趋势(15.4% vs 7.1%,p=0.064)。
要点
- 倾向性评分匹配分析显示,5-ALA引导切除后放置卡莫司汀 wafer 较单纯切除无显著生存获益(HR 0.97 [0.68-1.26],p=0.836)。
- 接受卡莫司汀 wafer 者伤口感染发生率有升高趋势(15.4% vs 7.1%,p=0.064)。
- 术中残留荧光肿瘤及术后MRI残留强化肿瘤显著预测生存期缩短。
核心结论
- 5-ALA引导切除后放置卡莫司汀 wafer 无额外获益。
- 术中残留荧光和术后残留强化病变对生存有负面影响。
研究设计与样本
- 回顾性队列研究,纳入2009年7月至2014年12月间260例经5-ALA引导切除、病理证实为WHO 2007 IV级胶质瘤的患者。
- 采用Kaplan-Meier法计算自手术起的生存曲线,log-rank检验比较组间生存曲线,Cox回归分析预测生存的变量,并使用倾向性评分匹配分析比较接受与未接受卡莫司汀 wafer 患者的生存。
主要发现
- 倾向性评分匹配分析显示,放置卡莫司汀 wafer 较单纯5-ALA引导切除无显著生存获益(HR 0.97 [0.68-1.26],p=0.836)。
- 接受卡莫司汀 wafer 者伤口感染发生率有升高趋势(15.4% vs 7.1%,p=0.064)。
- Cox回归分析显示,术中残留荧光肿瘤和术后MRI残留强化肿瘤显著预测生存期缩短。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Grade IV glioma is the most common and aggressive primary brain tumour. Gross total resection with 5-aminolevulinic acid (5-ALA) guided surgery combined with local chemotherapy (carmustine wafers) is an attractive treatment strategy in these patients. No previous studies have examined the benefit carmustine wafers in a treatment programme of 5-ALA guided resection followed by a temozolomide-based chemoradiotherapy protocol. The objective of this study was to examine the benefit of carmustine wafers on survival in patients undergoing 5-ALA guided resection. A retrospective cohort study of 260 patients who underwent 5-ALA resection of confirmed WHO 2007 Grade IV glioma between July 2009 and December 2014. Survival curves were calculated using the Kaplan-Meier method from surgery. The log-rank test was used to compare survival curves between groups. Cox regression was performed to identify variables predicting survival. A propensity score matched analysis was used to compare survival between patients who did and did not receive carmustine wafers while controlling for baseline characteristics. Propensity matched analysis showed no significant survival benefit of insertion of carmustine wafers over 5-ALA resection alone (HR 0.97 [0.68-1.26], p = 0.836). There was a trend to higher incidence of wound infection in those who received carmustine wafers (15.4 vs. 7.1%, p = 0.064). The Cox regression analysis showed that intraoperative residual fluorescent tumour and residual enhancing tumour on post-operative MRI were significantly predictive of reduced survival. Carmustine wafers have no added benefit following 5-ALA guided resection. Residual fluorescence and residual enhancing disease following resection have a negative impact on survival.
引用
- Sage W, Guilfoyle M, Luney C, et al. Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit. J Neurooncol. 2017. PMID: 29139095. doi:10.1007/s11060-017-2649-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。